Switch theme
Sign up to access all valuation multiples
Pure Health Holding PJSC is an integrated healthcare company in the United Arab Emirates with a cross-category ecosystem covering hospitals, clinics, diagnostics, insurance, pharmacies, research, health tech, and procurement along with an international footprint in the United States and the United Kingdom. The company's reportable segments are Hospital and Related Services, Health Insurance Services, Procurement and Supply, Diagnostic Services and Technology Services and Others. Key revenue is derived from its Hospitalisation and other related services segment through which it provides general healthcare operations including hospitalization, clinical, isolation/quarantine, vaccinations, and other services.
2021
56K+
LTM Revenue $7.4B
LTM EBITDA $1.2B
$9.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
PureHealth has a last 12-month revenue (LTM) of $7.4B and a last 12-month EBITDA of $1.2B.
In the most recent fiscal year, PureHealth achieved revenue of $7.0B and an EBITDA of $1.1B.
PureHealth expects next 12-month revenue of XXX and NTM EBITDA of XXX
See PureHealth valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $7.4B | XXX | $7.0B | XXX | XXX | XXX |
| Gross Profit | $2.0B | XXX | $1.8B | XXX | XXX | XXX |
| Gross Margin | 27% | XXX | 26% | XXX | XXX | XXX |
| EBITDA | $1.2B | XXX | $1.1B | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| EBIT | $772M | XXX | $542M | XXX | XXX | XXX |
| EBIT Margin | 10% | XXX | 8% | XXX | XXX | XXX |
| Net Profit | $527M | XXX | $466M | XXX | XXX | XXX |
| Net Margin | 7% | XXX | 7% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, PureHealth's stock price is AED 3 (or $1).
PureHealth has current market cap of AED 29.6B (or $8.0B), and EV of AED 35.2B (or $9.6B).
See PureHealth trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9.6B | $8.0B | XXX | XXX | XXX | XXX | $0.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, PureHealth has market cap of $8.0B and EV of $9.6B.
PureHealth's trades at 1.4x EV/Revenue multiple, and 8.5x EV/EBITDA.
Equity research analysts estimate PureHealth's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
PureHealth has a P/E ratio of 15.3x.
See valuation multiples for PureHealth and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8.0B | XXX | $8.0B | XXX | XXX | XXX |
| EV (current) | $9.6B | XXX | $9.6B | XXX | XXX | XXX |
| EV/Revenue | 1.3x | XXX | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | 7.9x | XXX | 8.5x | XXX | XXX | XXX |
| EV/EBIT | 12.4x | XXX | 17.7x | XXX | XXX | XXX |
| EV/Gross Profit | 4.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 15.3x | XXX | 17.3x | XXX | XXX | XXX |
| EV/FCF | 11.5x | XXX | 11.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPureHealth's last 12 month revenue growth is 12%
PureHealth's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $23K for the same period.
PureHealth's rule of 40 is 27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
PureHealth's rule of X is 46% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for PureHealth and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | 40% | XXX | XXX | XXX |
| Rule of 40 | 27% | XXX | 28% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 46% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $23K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 18% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Burjeel Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ramsay Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Athens Medical Centre | XXX | XXX | XXX | XXX | XXX | XXX |
| Compass Pathways | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PureHealth acquired XXX companies to date.
Last acquisition by PureHealth was XXXXXXXX, XXXXX XXXXX XXXXXX . PureHealth acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was PureHealth founded? | PureHealth was founded in 2021. |
| Where is PureHealth headquartered? | PureHealth is headquartered in United Arab Emirates. |
| How many employees does PureHealth have? | As of today, PureHealth has 56K+ employees. |
| Is PureHealth publicy listed? | Yes, PureHealth is a public company listed on ADS. |
| What is the stock symbol of PureHealth? | PureHealth trades under PUREHEALTH ticker. |
| When did PureHealth go public? | PureHealth went public in 2023. |
| Who are competitors of PureHealth? | Similar companies to PureHealth include e.g. Burjeel Holdings, Integral Diagnostics, Ramsay Health, Athens Medical Centre. |
| What is the current market cap of PureHealth? | PureHealth's current market cap is $8.0B |
| What is the current revenue of PureHealth? | PureHealth's last 12 months revenue is $7.4B. |
| What is the current revenue growth of PureHealth? | PureHealth revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of PureHealth? | Current revenue multiple of PureHealth is 1.3x. |
| Is PureHealth profitable? | Yes, PureHealth is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of PureHealth? | PureHealth's last 12 months EBITDA is $1.2B. |
| What is PureHealth's EBITDA margin? | PureHealth's last 12 months EBITDA margin is 16%. |
| What is the current EV/EBITDA multiple of PureHealth? | Current EBITDA multiple of PureHealth is 7.9x. |
| What is the current FCF of PureHealth? | PureHealth's last 12 months FCF is $832M. |
| What is PureHealth's FCF margin? | PureHealth's last 12 months FCF margin is 11%. |
| What is the current EV/FCF multiple of PureHealth? | Current FCF multiple of PureHealth is 11.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
